Items tagged with Scientific research
Structure of TB drug target determined (post)
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria.
TB: Researchers uncover how bacteria burst our cells (post)
Scientists based in Vienna unveil the complex molecular structure that causes lethal infections by Mycobacterium tuberculosis (Mtb). Their findings might have implications for potential therapies against antibiotic-resistant tuberculosis.
TB research sheds light on disease-related protein (post)
Each year the World Health Organization (WHO) recognizes World Health Day with the goal of spreading awareness for global health issues. The WHO names Tuberculosis (TB) as one of the top 10 causes of death worldwide and over 95 percent of those deaths occur in low- and middle-income countries. To improve the global health community’s understanding of TB and provide information that could help treat it, Notre Dame researchers have developed a new strain of the bacteria along with a new method to better study this deadly disease.
People with slender faces more likely to be left-handed, susceptible to TB (post)
Individuals with a slender lower face are about 25 percent more likely to be left-handed. This unexpected finding was identified in 13,536 individuals who participated in three national surveys conducted in the United States.
EPFL non-profit iM4TB awarded $2.45m for anti-TB drug clinical trials (post)
21.04.17 - The Bill & Melinda Gates foundation has awarded EPFL-based non-profit iM4TB $2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.
Critical Path Institute and TGen forge partnership to advance TB research (post)
TUCSON and FLAGSTAFF, Ariz., May 1, 2017 — The Critical Path to TB Drug Regimens (CPTR), an initiative of the Critical Path Institute (C-Path), has received a $1.1 million grant from the Bill & Melinda Gates Foundation to significantly enrich its Relational Sequencing TB Data Platform (ReSeqTB). To this end, C-Path and the Translational Genomics Research Institute (TGen) are excited to announce a new partnership to sequence at least 12,000 tuberculosis (TB) bacteria isolates from around the world.
IGIB uses novel drug discovery approach to identify drug targets in TB bacteria (post)
In a completely different approach to drug discovery, a team led by Dr. Samir K. Brahmachari, a J.C Bose National Fellow, at Delhi’s CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) has used a combination of approaches to predict potential drug targets in Mycobacterium tuberculosis, the TB-causing bacteria. The novel method not only helps in speeding up drug discovery by finding potential, non-toxic drug targets but will also cost far less by reducing the chances of failure. The results were published in the journal Scientific Reports.
A defence mechanism that can trap and kill TB bacteria (post)
A natural mechanism by which our cells kill the bacterium responsible for tuberculosis (TB) has been discovered by scientists at the Francis Crick Institute, which could help in the battle against antibiotic-resistant bacteria.
TB vaccine passes important milestone (post)
Investigators at Dartmouth’s Geisel School of Medicine announced that two new studies of DAR-901, their investigational vaccine against tuberculosis (TB), have moved it to the forefront of new vaccines in development for global control of this deadly infectious disease.
Page 23 of 74 · Total posts: 0
←First 22 23 24 Last→